Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 6;10:19272. doi: 10.1038/s41598-020-76285-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Oroxylin A alleviates immunoparalysis in CLP mice. (a) Mice were injected with oroxylin A (15, 30, 60, 90 mg/kg, i.p.) at the indicated times, and the effect of oroxylin A on the mortality of CLP mice was detected (n = 20). Kaplan–Meier curves and the log-rank test were used to compare mortality rates, *p < 0.05. (b) The effects of oroxylin A (30 mg/kg) on the bacterial clearance in blood, peritoneum lavage and spleen of CLP mice (n = 6). (c) The effects of oroxylin A (30 mg/kg) on the production of IL-1β (c1), TNFα (c2), IL-6 (c3) and IL-10 (c4) in serum were examined at the indicated times after CLP by ELISA (n = 6). (d) The effects of oroxylin A (30 mg/kg) on the production of IL-1β (d1), TNFα (d2), IL-6 (d3) and IL-10 (d4) in peritoneum lavage were examined at the indicated times after CLP by ELISA (n = 6). (e) Blood was collected at 96 h after CLP and stimulated with LPS (100 ng/ml) for 1 h. The level of TNFα was examined by ELISA (n = 3). (f) The percentages of CD4⁺ and CD8⁺ T cells in the spleen were examined at 96 h after CLP by flow cytometry (n = 3). The flow histograms are presented in Supplementary Figs. S17 and S18. (g) The ratio of CD4⁺/CD8⁺ T cells in the spleen was calculated according to the corresponding percentages of CD4⁺ and CD8⁺ T cells, respectively (n = 3). The data are represented as the mean ± SD (b–g), NS > 0.05 and ***p < 0.001, Student’s t test.